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Doxycycline, metronidazole and 
isotretinoin: Do they modify 
microRNA/mRNA expression 
profiles and function in murine 
T-cells?
Eugenia Becker1, Susan Bengs1, Sirisha Aluri2, Lennart Opitz2, Kirstin Atrott1, 
Claudia Stanzel1, Pedro A. Ruiz Castro1, Gerhard Rogler1 & Isabelle Frey-Wagner1
Inflammatory bowel disease (IBD) may develop due to an inflammatory response to commensal gut 
microbiota triggered by environmental factors in a genetically susceptible host. Isotretinoin (acne 
therapy) has been inconsistently associated with IBD onset and flares but prior treatment with 
antibiotics, also associated with IBD development, complicates the confirmation of this association. 
Here we studied in mice whether doxycycline, metronidazole or isotretinoin induce epigenetic 
modifications, and consequently change T-cell mRNA expression and/or function directly after 
treatment and after a 4 week recovery period. Isotretinoin induced IL-10 signaling in Tregs and naive 
T-cells directly after treatment and reduced effector T-cell proliferation alone and in co-culture with 
Tregs. Metronidazole activated processes associated with anti-inflammatory pathways in both 
T-cell subsets directly after the treatment period whereas doxycycline induced an immediate pro-
inflammatory expression profile that resolved after the recovery period. Long-term changes indicated 
an inhibition of proliferation by doxycycline and induction of beneficial immune and metabolic 
pathways by metronidazole. Persistent alterations in microRNA and mRNA expression profiles after 
the recovery period indicate that all three medications may induce long-term epigenetic modifications 
in both T-cell subsets. Yet, our data do not support the induction of a long-term pro-inflammatory 
phenotype in murine Tregs and naive T-cells.
Inflammatory bowel diseases (IBD) with the two main forms, Crohn’s disease (CD) and ulcerative colitis (UC), 
are chronic and relapsing inflammatory conditions of the gastrointestinal tract that affect an increasing number 
of patients worldwide1. The precise pathogenesis of IBD is multifactorial and is not completely elucidated yet. It is 
generally considered that environmental factors represent an important contributor to the pathogenesis of IBD by 
triggering an inappropriate and progressive immune response to the commensal gut microbiota in a genetically 
predisposed host2. To date, genome-wide association studies have identified more than 240 IBD susceptibility 
loci, affecting genes involved in immune regulation, mucosal immune response, autophagy and epithelial barrier 
function3–5.
Currently available data support the concept that IBD is a polygenic disease and suggest that non-genetic 
modifications involved in regulatory processes might have an impact on susceptibility and severity of disease6. 
Mechanisms of gene regulation that do not alter the basic sequence of DNA are called epigenetic regulations and 
have been studied extensively over the last few years. These studies have shown that epigenetic modifications are 
associated with a variety of diseases, e.g. IBD7,8, multiple sclerosis9, psoriasis10 and systemic lupus erythemato-
sus11. The molecular basis of epigenetic regulation is complex. Importantly, changes may remain through cell divi-
sion, and last for many generations (long-term effects)12. So far, three major epigenetic modifications have been 
identified: DNA methylation, histone modifications and differential microRNA expression. MicroRNAs are small 
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non-coding RNA (18–24 nucleotides) molecules binding to complementary sequences in the 3′ untranslated 
region (3′ -UTR) of their target mRNAs leading to sequestration, degradation or storage of these target mRNAs13.
Mounting evidence demonstrates that antibiotics can impact on the occurrence of IBD and IBD flares, as 
well as increase the risk of developing IBD in children and adults, indicating long-term effects after medication 
with antibiotics14–18. Moreover, some case reports have shown a potential association between isotretinoin, a 
non-antimicrobial drug used for the treatment of severe acne, and the development of IBD during medication, 
immediately after or even weeks or months after cessation of therapy19–21. Yet, others were unable to confirm these 
findings22–24. Isotretinoin is typically used in patients unresponsive to antibiotics15,25. Hence, any attempt to con-
firm a causal relationship between isotretinoin and IBD is confounded by prior antibiotic treatment.
In the present study, we have determined microRNA expression, mRNA expression as well as functional 
parameters in murine naive and regulatory T-cells to evaluate immunomodulatory effects of doxycycline (used 
in acne therapy and associated with IBD), metronidazole (one of the preferred antibiotics in IBD treatment), and 
isotretinoin. To capture immediate and persistent effects, samples were taken directly after a 2 week treatment 
period and 4 weeks after the last drug administration. The latter time point is henceforth referred to as recovery 
phase.
Results
In order to investigate direct and long-term alterations in murine splenic T-cell subsets upon oral isotreti-
noin, metronidazole or doxycycline treatment (Fig. 1), microRNA and mRNA expression were assessed by 
Next-Generation Sequencing. We first analyzed direct and long-term effects in naive T-cells (CD4+ CD62L+ ) to 
study an influence on largely undifferentiated cells. We further investigated the impact on Tregs (CD4+ CD25+ ) 
to unravel modifications that might impair Tregs in a way that favors an inflammatory status.
Correlation of predicted microRNA targets and mRNA expression directly after isotretinoin or 
antibiotic treatment in naive T-cells. All three orally administered agents led to differentially expressed 
microRNAs, as defined by (|log2 (fold change)| ≥ 1, P-value ≤ 0.001), in naive T-cells directly after the treatment 
period (Fig. 2). 3 microRNAs (microRNA-3971, − 3962, − 374c-5p) were significantly overexpressed in isotreti-
noin treated animals and potentially down-regulate 777 microRNA targets as defined with TargetScan (Fig. 2A). 
Pathway analysis by MetaCore of these microRNA targets identified gastrin-mediated effects on cell growth and 
proliferation (P = 8.47E-08), cytoskeleton remodeling (P = 9.60E-08) and the c-Jun N terminal kinase (JNK) 
signaling pathway (P = 1.31E-07) as the most strongly affected. Interestingly, the transcriptome analysis of naive 
T-cells revealed that 2 weeks of isotretinoin treatment led to an increase in the expression of mRNAs, as defined by 
(|log2 (fold change)| ≥ 0.5, P-value ≤ 0.001), involved in interleukin (IL)-10 signaling (Bcl-2, Fc gamma RIIalpha, 
Mmp-9 and Socs3) (P = 3.64E-07) and a down-regulation of genes involved in pro-inflammatory processes, such 
Figure 1. Experimental design. BALB/c female mice were treated with isotretinoin, rapeseed oil (isotretinoin 
vehicle), metronidazole, doxycycline or water (antibiotics vehicle) by daily oral gavage for 2 weeks. (A) Splenic 
T-cells were isolated after 2 weeks of treatment (immediate effects) and after a recovery phase of 4 weeks after 
treatment cessation (long-term effects). For isotretinoin and rapeseed oil, 2-5 replicates (pool of 2-4 animals or 
no pooling) per group were sampled immediately after treatment and 2-5 replicates after the recovery phase. For 
metronidazole, doxycycline and water, 2 replicates (pool of 6 animals) were sampled per time point and group. 
(B) No differences between treatment groups were registered with respect to body weight for all time points.
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as interferon (IFN) signaling (Isg15) (P = 1.30E-02) and nuclear factor (NF)κ B activity (Histone 4) (P = 1.84E-
02) suggesting a direct anti-inflammatory effect of isotretinoin on naive T-cells. No overlap between predicted 
microRNA targets and differentially expressed mRNAs could be observed.
Upon metronidazole treatment, the expression of 5 microRNAs was significantly lower as compared to 
the respective control group (Supplementary Table 1). The down-regulation of these microRNAs resulted in 
the prediction of 340 potentially up-regulated microRNA targets associated with IL-2 activation and signal-
ing (P = 3.41E-06), cytoskeleton remodeling (P = 8.53E-06) and epithelial-to-mesenchymal-transition (EMT) 
(P = 2.20E-06) (Fig. 2B). However, metronidazole treatment had only minor effects on mRNA expression 
in splenic naive T-cells, with only 14 mRNAs being significantly overexpressed in comparison to the control 
group. Among these mRNAs, IL-17r was strongly up-regulated (14-fold, P  =  1.80E-06) directly after treatment. 
However, Metacorewas unable to build a network around IL-17r despite its strong up-regulation (Fig. 2B). There 
was no overlap between predicted microRNA targets and differentially expressed mRNAs.
Doxycycline treatment induced significant overexpression of microRNA-144-3p that resulted in the predic-
tion of 493 potentially down-regulated microRNA targets involved in protein kinase A (PKA) (P = 9.01E-06), 
protein kinase B (known as AKT) (P = 2.42E-04) and nuclear factor of activated T-cells (NFAT) signaling path-
ways (P = 3.81E-04) (Fig. 2C and Supplementary Table 1). Transcriptome analysis of doxycycline treated animals 
showed an up-regulation of 21 mRNAs involved in pro-inflammatory pathways, such as NFκ B signaling (Baff, 
IL-1beta) (P = 3.42E-03) and IL-13 signaling (Alox15, Rsnb) (P = 2.56E-03). Notably, metronidazole and doxy-
cycline strongly downregulated mRNAs involved in cell adhesion (P = 1.41E-06; P = 5.15E-08) and metabolism 
processes (P = 2.47E-05; 2.15E-06) in naive T-cells directly after treatment (Fig. 2B and C, right). No overlap 
between predicted microRNA targets and differentially expressed mRNAs could be observed.
Figure 2. Correlation of predicted microRNA targets and mRNA expression directly after isotretinoin or 
antibiotic treatment in naive T-cells (direct effect). Analysis of mathematically predicted microRNA targets 
was performed with TargetScan or TargetScan custom for (A) isotretinoin (iso), (B) metronidazole (metro) and 
(C) doxycycline (doxy) treated animals compared to control groups (left panels). Identification of differentially 
expressed mRNAs was performed with the following thresholds: |log2 (fold change)| ≥ 0.5, P-value ≤ 0.001 
(right panels). Three of the most significant pathways associated with potentially up-regulated microRNA 
targets as predicted from down-regulated microRNAs and mRNAs are shown in the green sections whereas 
down-regulated microRNA targets (as predicted from up-regulated microRNAs) and mRNAs are depicted in 
the red sections. Shared candidates between predicted microRNA targets and experimentally derived mRNAs 
are displayed in the centers of the respective section. The pathway analysis was performed with MetaCore by 
Thomson Reuters.
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Correlation of predicted microRNA targets and mRNA expression after the recovery phase in 
naive T-cells of isotretinoin and antibiotic treated animals. After the 4-week recovery period (Fig. 3), 
previous treatment with isotretinoin was followed by a down-regulation of 35 microRNAs in naive T-cells. 
This large number of differentially expressed microRNAs led to a prediction of 11′ 806 potentially up-regulated 
microRNA targets predominantly involved in cytoskeleton remodeling (P = 1.70E-18) and insulin-growth-factor 
signaling (P = 9.61E-17). When we analyzed changes in mRNA expression after the recovery period in isotreti-
noin treated animals, significantly overexpressed mRNAs were involved in Ca(2+)- and NFAT signaling 
(P = 1.70E-05; 3.96E-05) as well as in B cell receptor-associated pathways (P = 5.89E-09). We found 21 overlaps 
between mathematically derived microRNA targets and experimentally derived mRNAs. The mRNAs thereof 
are involved in signal transduction in immune cells, e.g. Ciita, Lrrk2, Marcks, and antigen presentation responses 
(CD24a, CD8a), suggesting relevant epigenetic changes important for T-cell function. Isotretinoin led to a sig-
nificant down-regulation of 7 mRNAs only, indicating minor effects on mRNA suppression in naive T-cells after 
the recovery phase.
Metronidazole treatment had no significant long-term effects on microRNA expression in naive T-cells in 
comparison to the control group. Despite a lack of epigenetic regulation at microRNA level, metronidazole 
treatment led to increased expression of a number of mRNAs after the recovery period. These were involved 
in cytoskeleton remodeling (P = 2.13E-02) and, surprisingly, in the differentiation into Tregs (P = 2.26E-02) 
through up-regulation of Foxp3 (Supplementary Table 2). However, the number of mRNAs with significantly 
higher expression was relatively small (18 mRNAs) indicating a moderate long-term effect. In the opposite direc-
tion, metronidazole treatment led to a reduced expression of 34 mRNAs which were identified to be associated 
with IL-12 signaling (P = 1.49E-02) and T helper (Th)17 differentiation (Irf4) (P = 2.26E-02). The up-regulation 
Figure 3. Correlation of predicted microRNA targets and mRNA expression after the recovery phase in 
naive T-cells of isotretinoin and antibiotic treated animals (long-term effect). Analysis of mathematically 
predicted microRNA targets was performed with TargetScan or TargetScan custom for (A) isotretinoin (iso), 
(B) metronidazole (metro) and (C) doxycycline (doxy) treated animals compared to control groups (left 
panels). Differentially expressed mRNAs were identified with the following thresholds: |log2 (fold change)| 
≥ 0.5, P-value ≤ 0.001 (right panels). Three of the most significant pathways associated with up-regulated 
microRNA targets (down-regulated microRNAs) and mRNAs are shown in the green sections whereas down-
regulated microRNA targets (up-regulated microRNAs) and mRNAs are depicted in the red sections. Shared 
candidates between predicted microRNA targets and experimentally derived mRNAs are displayed in the 
centers of the respective section. The pathway analysis was performed with MetaCore by Thomson Reuters.
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of the expression of Treg differentiation factors and the down-regulation of expression of Th1 and Th17 associated 
mRNAs may be interpreted as an overall anti-inflammatory long-term effect.
Doxycycline treatment significantly decreased the expression of only 1 microRNA (microRNA-144-5p) after 
the recovery period in naive T-cells. The decrease of microRNA-144-5p resulted in the prediction of 42 potentially 
up-regulated microRNA targets involved in cell adhesion (P = 1.12E-03), cytoskeleton (P = 8.73E-04) and metab-
olism (P = 1.03E-03) pathways. At transcriptome level 13 mRNAs likewise involved in metabolism (P = 1.40E-02) 
and G-protein signaling (P = 3.47E-03) were overexpressed, indicating consistent regulation at microRNA and 
mRNA level. However, no overlaps between predicted microRNA targets and differentially expressed mRNAs 
were determined indicating a minor effect of microRNA mediated regulation on gene expression in naive T-cells 
after the recovery phase in doxycycline treated animals.
Correlation of predicted microRNA targets and mRNA expression directly after isotretinoin 
and antibiotic treatment in Tregs. In addition to the analysis of naive T-cells, we analyzed changes in the 
expression of microRNAs in Tregs directly after the treatment (immediate effects).
Treatment with isotretinoin induced overexpression of 7 microRNAs, which potentially down-regulate 
227 microRNA targets involved in apoptosis (P = 7.44E-06), fat cell differentiation (P = 2.91E-05) and can-
cer pathways (P = 9.54E-05) (Fig. 4A). For the 4 down-regulated microRNAs after isotretinoin treatment, 
1′ 270 potentially up-regulated mRNAs were predicted by TargetScan being involved in cytoskeleton remodeling 
(P = 5.42E-09) and developmental pathways (P = 2.14E-08). Interestingly, mRNA expression analysis showed that 
IL-10 signaling (CD23, Ikbz, Mmp-9 and Socs3) (P = 4.20E-07) was activated upon isotretinoin treatment also in 
Tregs, like we had found for naive T-cells, indicating a direct anti-inflammatory effect of isotretinoin on both 
T-cell subsets. Significant down-regulation of mRNAs involved in IL-12 signaling (P = 2.53E-04) and Th1/Th2 
differentiation (Ifnγ, IL-18r1, T-bet, CD40L) (P = 3.47E-04) in Tregs directly after isotretinoin treatment further 
Figure 4. Correlation of predicted microRNA targets and mRNA expression directly after isotretinoin 
or antibiotic treatment in Tregs (direct effect). Analysis of mathematically predicted microRNA targets was 
performed with TargetScan or TargetScan custom for (A) isotretinoin (iso), (B) metronidazole (metro) and  
(C) doxycycline (doxy) treated animals compared to control groups (left panels). Differentially expressed 
mRNAs were identified with the following thresholds: (|log2 (fold change)| ≥ 0.5, P-value ≤ 0.001 (right panels). 
Three of the most significant pathways associated with up-regulated microRNA targets (down-regulated 
microRNAs) and mRNAs are shown in the green sections whereas down-regulated microRNA targets  
(up-regulated microRNAs) and mRNAs are depicted in the red sections. Shared candidates between predicted 
microRNA targets and experimentally derived mRNAs are displayed in the centers of the respective section. The 
pathway analysis was performed with MetaCore by Thomson Reuters.
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supports a direct anti-inflammatory effect of isotretinoin. There was no overlap between predicted microRNA 
targets and differentially expressed mRNAs.
Directly after metronidazole treatment microRNA expression was not affected. Pathway analysis of the 102 
overexpressed mRNAs in response to metronidazole treatment revealed that activation of genes involved in 
G-protein signaling (P = 4.87E-04), memory generation (P = 2.56E-05) and - like for the long-term effect in naive 
T-cells - differentiation of natural Tregs (CD4, Foxp3, Gitr, CD25, TCRalpha/beta) (P = 5.46E-07). In the opposite 
direction, 883 mRNAs involved in cell cycle pathways (P = 2.08E-12) and immune responses (P = 7.56E-11) were 
significantly down-regulated (Fig. 4B).
Doxycycline treatment had a direct impact on the expression of 2 microRNAs in Tregs: microRNA-100-5p and 
-1249-3p. The up-regulation of microRNA-100-5p predicts the down-regulation of 36 microRNA targets linked 
to G-protein-associated signaling (P = 4.08E-04) and cell proliferation processes (P = 1.53E-04). The 8 mRNAs 
that could be targeted by microRNA-1249-3p are important in Ephrin signaling (P = 2.265E-4) and colorectal 
cancer (P = 1.602e-2). Doxycycline increased the expression of 121 mRNAs associated with pro-inflammatory 
responses, such as IL-18 signaling (Cox-2, IL-1β, IL18rap, Mmp-9) (P = 3.11E-04), and down-regulated the 
expression of 45 mRNAs involved in cell cycle processes (P = 1.81E-09). However, none of these mRNAs were 
among the mathematically predicted microRNA targets. In summary, doxycycline appears to induce inflamma-
tory processes while inhibiting proliferation in Tregs immediately after treatment, yet no epigenetic regulation by 
microRNAs seems to be responsible for the effects observed at mRNA level.
Correlation of predicted microRNA targets and mRNA expression after the recovery period in 
Tregs of isotretinoin and antibiotic treated animals. After the recovery phase, significant changes in 
microRNA expression could be observed in Tregs of animals treated with isotretinoin, metronidazole or doxycy-
cline treated animals, with overlaps between predicted microRNA target and mRNA data sets within the respec-
tive treatment groups indicating possible epigenetic regulation (Fig. 5).
Previous isotretinoin treatment led to significantly reduced expression of 5 microRNAs resulting in the 
mathematical prediction of 1′ 125 potentially up-regulated mRNAs by TargetScan. These predicted microRNA 
targets were annotated to be involved in cell adhesion (P = 3.96E-07) and cytoskeleton remodeling processes 
(P = 7.98E-12). When correlating the prediction based microRNA data with overexpressed mRNAs, we identified 
1 overlap, Sox13 (Fig. 5A). The transcriptome analysis further showed a significant overexpression of mRNAs 
implicated in NFAT signaling (P = 5.19E-08), granulocyte-colony stimulating factor (G-CSF) induced differ-
entiation (P = 6.29E-06) and B-cell receptor (BCR) responses (P = 5.91E-13), whereas down-regulated mRNAs 
were associated with cell cycle regulation (P = 1.89E-02), as well as activator protein (AP)-1 (P = 2.05E-02) and 
Ca(2+)-dependent processes (P = 2.32E-02).
After the recovery period, previous metronidazole treatment affected the expression of a total of 11 microR-
NAs in Tregs. For the 8 microRNAs with significantly increased expression, 1′ 228 possible microRNA targets 
were predicted and were enriched in different pathways, such as NFAT (P = 7.01E-10) and tumor necrosis factor 
receptor (TNFR)2 signaling (P = 1.98E-08), as well as in epigenetic regulation of gene expression (P = 4.21E-07). 
Correlating these potentially down-regulated microRNA targets with the 282 down-regulated mRNAs, we found 
17 common mRNAs between both data sets. The 282 down-regulated mRNAs were involved in transcriptional 
regulation, phosphatidylinositol 3,4,5-trisphosphate (PIP3) (P = 4.13E-06) and NFAT signaling (P = 1.57E-05) 
(Fig. 5B). Moreover, the down-regulation of 3 microRNAs (microRNA-30e-5p, -340-5p, -142b) resulted in a 
prediction of 2′ 324 potentially up-regulated microRNA targets associated with bone morphogenetic proteins 
(BMP) (P = 5.328E-8), Ephrin (P = 2.44E-12) and cytoskeleton remodeling processes (P = 1.68E-07). In ani-
mals treated previously with metronidazole we observed an increase in the expression of 236 mRNAs after the 
recovery period, known to be involved in metabolism (P = 7.81E-03) and Rab5a-dependent transport pathways 
(P = 8.46E-03). 14 mRNAs were shared between the up-regulated microRNA target and mRNA data sets suggest-
ing possible epigenetic regulation.
Previous doxycycline treatment led to differential expression of 4 microRNAs in Tregs. The analysis of 
microRNA targets of the microRNA-486 family indicated 298 potentially down-regulated mRNAs. 11 of those 
were also found within the data set of significantly downregulated mRNAs (806 mRNAs). The affected pro-
cesses included IL-2 (P = 1.71E-06), CDC42 signaling (P = 5.16E-06) and cell growth (P = 4.86E-07) for the 
down-regulated microRNA targets, and cell cycle (P = 2.63E-09) and PIP3 signaling (P = 6.02E-09) for the 
down-regulated mRNAs. Pathway analysis of the 289 up-regulated mRNAs indicated that the expression of genes 
involved in immune responses, such as Treg function (Ctla-4, IL-10) (P = 5.16E-04), PKA signaling (P = 1.22E-03) 
and differentiation of CD8+ T-cells (P = 4.37E-04) was affected, suggesting a rather immunosuppressive pheno-
type in Tregs after the recovery phase in doxycycline treated animals.
Isotretinoin inhibits effector T-cell proliferation immediately after treatment cessation, but 
does not provoke long-term effects. To explore the direct and long-term effects of isotretinoin on T-cell 
function, we assessed the proliferation of effector T-cells (Teffs; CD4+ CD25− ) by monitoring the fluorescence 
signal of carboxyfluoresceinsuccinimidyl ester (CFSE). Teffs from vehicle- or isotretinoin-treated animals were 
co-cultured either with Tregs from mice under the same treatment (e.g. Treg(ctrl)/Teff(ctrl)) or combining dif-
ferent treatments in a mixed setting, e.g. Treg(ctrl)/Teff(iso), to discriminate how T-cell proliferation is affected 
by isotretinoin treatment.
Interestingly, stimulated Teff(iso) proliferated less compared to Teff(ctrl) under basal conditions (Fig. 6A). 
Co-cultures of Teff(ctrl) or Teff(iso) with unlabeled Teffs (unlab) at a 1/2 or 1/8 ratio under the same treatment 
conditions, showed similar proliferation patterns (Fig. 6B and C upper panels). However, when co-culturing 
Teff(iso) with Treg(iso) at a 1/2 ratio, the inhibition of Teff(iso) proliferation was enhanced compared to Teff(ctrl) 
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co-cultured with Treg(ctrl) (Fig. 6B and C lower panels). These effects were partly reversed when Treg(iso) were 
cultured at a 1/8 ratio.
Culturing T-cells using different combinations (Teff(ctrl)/Treg(iso) and Teff(iso)/Treg(ctrl)) we observed 
reduced proliferation of Teff(iso) co-cultured with Treg(ctrl) compared to Teff(ctrl) cultured with Treg(iso) 
(Fig. 6D and E lower panels) while proliferation in controls (unlab/Teff(iso or ctrl)) was unaffected (Fig. 6D and E 
upper panels). In summary, these results indicate that Teff isolated from isotretinoin treated animals are more 
sensitive to inhibition of proliferation by Tregs, independently of whether the Tregs had been exposed to isotreti-
noin or not.
When we performed the experiment with T-cells isolated after the 4-weeks recovery period to study long-term 
effects, we did not observe any significant differences in Teff proliferation (Fig. 7).
Isotretinoin induces Socs3 protein expression in Jurkat cells, but does not activate the 
p38-ERK-MSK1 signaling pathway. To investigate the underlying mechanisms of isotretinoin-mediated 
regulation of IL-10 signaling, we studied the expression of proteins along the MAPK p38-MSK1 pathway. Some 
publications have demonstrated an extra-nuclear function of the retinoic acid receptor (RAR) in fibroblasts, 
mammary breast cancer cells, keratinocytes and macrophages26,27. RAR activation by retinoic acid (RA) results 
in the phosphorylation of MAPK p38-MSK1 proteins that eventually contribute to the expression of IL-10 and 
DUSP1. Accordingly, we identified an induction of IL-10 signaling (Figs 2 and 4) and an increase of DUSP1 
(Supplementary Table 2) in both T-cell subsets of isotretinoin treated animals directly after treatment. When we 
treated Jurkat cells with isotretinoin we observed only a trend towards an increase of Socs3 protein expression 
(Fig. 8A) while p38 and MSK1 phosphorylation was not affected (Fig. 8B–D) suggesting that isotretinoin regu-
lates IL-10 and DUSP1 expression through an alternative mechanism in Jurkat cells.
Figure 5. Correlation of predicted microRNA targets and mRNA expression after the recovery phase in 
Tregs of isotretinoin and antibiotic treated animals (long-term effect). Analysis of mathematically  
predicted microRNA targets was performed with TargetScan or TargetScan custom for (A) isotretinoin (iso), 
(B) metronidazole (metro) and (C) doxycycline (doxy) treated animals compared to control groups (left panels). 
Selection of differentially expressed mRNAs was performed with the following thresholds: |log2 (fold change)| 
≥ 0.5, P-value ≤ 0.001 (right panels). Three of the most significant pathways associated with up-regulated 
microRNA targets (down-regulated microRNAs) and mRNAs are shown in the green sections whereas down-
regulated microRNA targets (up-regulated microRNAs) and mRNAs are depicted in the red sections. Shared 
candidates between predicted microRNA targets and experimentally derived mRNAs are displayed in the 
centers of the respective section. The pathway analysis was performed with MetaCore by Thomson Reuters.
www.nature.com/scientificreports/
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Discussion
In the present study, we show differential effects of doxycycline, metronidazole and isotretinoin on microRNA 
and mRNA expression in murine Tregs and naive T-cells with different expression patterns directly after the 
treatment and at the end of the recovery period. Interestingly, analysis of putative microRNA targets and mRNA 
expression indicated a direct anti-inflammatory effect for isotretinoin as evidenced by the induction of IL-10 
signaling in Tregs and naive T-cells, and a reduction in effector T-cell proliferation indicating no effects that 
might suggest pathologic effects. Both antibiotics led to a reduced expression of signaling molecules involved in 
proliferation, which was still observed after the recovery phase in the case of doxycycline. Doxycycline treated 
animals showed activation of pro-inflammatory pathways in Tregs and naive T-cells directly after the treatment 
phase, but not after the recovery period. In contrast, metronidazole led to an induction of an anti-inflammatory 
profile in Tregs immediately after treatment, whereas in naive T-cells this induction was observed only after the 
recovery period.
The differential microRNA and mRNA expression profile in doxycycline and metronidazole treated ani-
mals after the recovery period indicates that these antibiotics have the potential to induce long-term changes 
in the immune phenotype of Tregs and naive T-cells. These persistent effects on splenic T-cells suggest that 
both antibiotics have immunosuppressive properties. Isotretinoin induced direct anti-inflammatory effects at 
microRNA, mRNA and functional level with long-term effects on NFAT-, BCR-, PI3K/AKT-relevant pathways 
as well was Ca(2+)- and G-CSF-mediated processes.The analysis of microRNA expression and their involvement 
in different cell processes is still challenging due to the lack of normalization strategies and the complexity of 
Figure 6. Immediate effects of isotretinoin on Treg suppression/Teff proliferation. Proliferation of Teffs 
was assessed by FACS analysis by measuring the dilution of the intensity of CFSE. (A) Proliferation of Teffs for 
the control group (top) and isotretinoin group (bottom) at basal conditions. (B) Unlabeled Teffs co-cultured 
with CFSE-labeled Teffs from vehicle treated animals at a 1/2 or 1/8 ratio (top) or Tregs co-cultured with Teffs 
from the controls at a 1/2 or 1/8 ratio (bottom). (C) Unlabeled Teffs co-cultured with CFSE-labeled Teffs from 
isotretinoin treated animals at a 1/2 or 1/8 ratio (top) or Tregs co-cultured with Teffs from the controls at a 
1/2 or 1/8 ratio (bottom). (D) Inverse setting: unlabeled Teffs from controls were cultured with CFSE-labeled 
Teffs from isotretinoin treated animals at a 1/2 or 1/8 ratio or Tregs from controls cultured with Teffs from the 
isotretinoin condition. (E) Inverse setting: unlabeled Teffs from isotretinoin treated animals were cultured with 
CFSE-labeled Teffs from control animals at a 1/2 or 1/8 ratio or Tregs from isotretinoin treated animals were 
cultured with Teffs from controls. Shown are representative graphs of two independent experiments. Solid line: 
stimulated CFSE-labeled Teffs. Dashed line: unstimulated CFSE-labeled Teffs. Abbreviations: Teffs, effector 
T-cells (CD4+ CD25− ); Tregs, regulatory T-cells (CD4+ CD25+ ); unlab, unlabeled Teffs; ctrl, vehicle treated 
animals; iso, isotretinoin treated animals; 1/2 and 1/8 ratio of unlab or Tregs; FACS, fluorescence-activated cell 
sorting; CFSE, carboxyfluoresceinsuccinimidyl ester.
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microRNA-mRNA interactions. Combined analysis of microRNA and mRNA expression in T-cells applying 
Next-Generation Sequencing is sparse. Our study shows for the first time a thorough characterization of possible 
microRNA-mediated mRNA regulation in T-cell subsets that might pave the way for further investigations aimed 
to understand the contribution of microRNAs to T-cell differentiation and function. Our findings are based on 
a limited number of biological replicates. For identification of reliably regulated microRNAs we applied strict 
thresholds in our bioinformatic processing and candidate selection (|log2 (fold change)| ≥ 1, P-value ≤ 0.001). Yet, 
the limited number of replicates as well as the strict thresholds for identification of altered microRNA expression 
might preclude identification of relevant microRNAs. Comparisons between microRNA and mRNA expression 
are further complicated as sequence based prediction of microRNA targets is limited by the small size of microR-
NAs and the fact that partial pairing is often sufficient28.
Our data set shows, that directly after treatment no correlation between microRNA and mRNA changes can 
be observed whereas at the later time point some overlap between predicted microRNA targets and differential 
mRNA expression can be observed. We found no overlap between predicted microRNA targets and differentially 
expressed mRNAs directly after treatment for none of the applied agents, suggesting that directly after treatment 
other mechanisms of the complex regulation of gene expression (e.g. chromatin structure and interaction of tran-
scription factors in the regulation of mRNA transcription29) outweigh the influence of microRNAs.
So far, only few studies compared the impact of microRNA mediated gene expression regulation with the 
impact of other mechanisms, but in general the impact of microRNAs is considered weak30. In a study inves-
tigating the impact of overexpression or knockout of a certain microRNA on protein expression, Baek et al. 
Figure 7. Long-term effects of isotretinoin on Treg suppression/Teff proliferation. Proliferation of Teffs 
was assessed by FACS analysis by measuring the dilution of the intensity of CFSE. (A) Proliferation of Teffs for 
the control group (top) and isotretinoin group (bottom) at basal conditions. (B) Unlabeled Teffs co-cultured 
with CFSE-labeled Teffs from vehicle treated animals at a 1/2 or 1/8 ratio (top) or Tregs co-cultured with Teffs 
from the controls at a 1/2 or 1/8 ratio (bottom). (C) Unlabeled Teffs co-cultured with CFSE-labeled Teffs from 
isotretinoin treated animals at a 1/2 or 1/8 ratio (top) or Tregs co-cultured with Teffs from the controls at a 
1/2 or 1/8 ratio (bottom). (D) Inverse setting: unlabeled Teffs from controls were cultured with CFSE-labeled 
Teffs from isotretinoin treated animals at a 1/2 or 1/8 ratio or Tregs from controls cultured with Teffs from the 
isotretinoin condition. Inverse setting: unlabeled Teffs from isotretinoin treated animals were cultured with 
CFSE-labeled Teffs from control animals at a 1/2 or 1/8 ratio or Tregs from isotretinoin treated animals were 
cultured with Teffs from controls. Shown are representative graphs of three independent experiments. Solid 
line: stimulated CFSE-labeled Teffs. Dashed line: unstimulated CFSE-labeled Teffs. Abbreviations: Teffs, effector 
T-cells (CD4+ CD25− ); Tregs, regulatory T-cells (CD4+ CD25+ ); Unlab, unlabeled Teffs; ctrl, vehicle treated 
animals; iso, isotretinoin treated animals; 1/2 and 1/8 dilution of Unlab or Tregs; FACS, fluorescence-activated 
cell sorting; CFSE, carboxyfluoresceinsuccinimidyl ester.
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concluded that microRNA probably act to fine-tune protein expression31. In some studies a better correlation 
between microRNA expression and protein levels than between microRNA and mRNA levels was observed32. We 
therefore suggest that directly after the treatment other mechanisms of gene expression regulation superimpose 
subtle regulations mediated by microRNAs.
One of the goals of our study was to investigate whether isotretinoin or antibiotic treatment can lead to epi-
genetic modifications that might contribute to the association seen between antibiotic treatment and develop-
ment of IBD. Epigenetic modifications like DNA methylation and histone modifications can regulate microRNA 
expression and thereby lead to long-term effects on gene expression regulation33. The finding that we do not see 
an overlap between predicted microRNA targets directly after treatment but after the recovery period may suggest 
that subtle effects mediated by microRNAS become more visible and effective when stronger, direct mechanisms 
do not act any more.
We here focused on the comparison of changes at microRNA and mRNA level between isotretinoin, metroni-
dazole and doxycycline treated groups and the respective vehicle control groups directly after the treatment and 
after the recovery period. In addition, analysis of altered microRNA and mRNA expression within a treatment 
groups over time provides insight how the genetic signature evolves during the recovery period. However, it is 
difficult to discriminate between changes over time due to T-cell maturation and changes from treated back to 
untreated These data can be found in Supplementary Figures 2 and 3 and Supplementary Tables 3 and 4. For 
identification of differentially expressed microRNAs and mRNAs over time within a treatment group the same 
thresholds as in the comparison to the control groups (|log2 (fold change)| ≥ 1, P-value ≤ 0.001 for microRNAs 
and |log2 (fold change)| ≥ 0.5, P-value ≤ 0.001 for mRNAs) were applied.
Knowledge on altered microRNA expression in IBD has increased immensely over the past few years. An 
increase of microRNA-21, -29, -130, -146, -155, -195, -196–214, -223, -375, whereas a decrease of microRNA-10, 
-124 have been observed in IBD patients6,34–38. Interestingly, in our studies IBD-associated microRNA-130, 
-195, -196, -223, -375 were down-regulated in Tregs or naive T-cells after isotretinoin treatment, indicating that 
isotretinoin does not induce a microRNA expression pattern similar to the one observed in IBD patients.
Figure 8. Isotretinoin influences Socs3 expression in Jurkat cells but does not activate the p38-ERK-MSK1 
signaling pathway. Jurkat cells were treated with isotretinoin (10 ng/ml) and PMA (100 ng/ml) in combination with 
anti-CD3/CD28 stimulation and samples were taken at the indicated time points. (A-D) Representative Western 
Blots show levels of (A) Socs3, (B) p-ERK (Tyr42/Tyr44), (C) p-p38 (Thr180/Tyr182) and (D) p-MSK1 (Thr581). 
The blots were cropped for improving clarity and full-length blots are presented in Supplementary Figure 2. 
The solid line on each blot depicts a vertically sliced area where the gel size maker was cropped. Expression was 
normalized to total protein content or anti-GAPDH (loading control); the graphs depict densitometric analysis 
(n = 3). Significant differences in comparison to the controls are denoted by asterisk (*P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001).
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The contribution of retinoic acid (RA) to Treg differentiation is well described39–42. Therefore, it is plausible 
that isotretinoin, as a RA derivate, might also influence T-cell fate. The role of specific microRNAs in T helper 
(Th) cell differentiation has been well documented, e.g. microRNA-29 in Th1 cells, microRNA-126 in Th2 cells, 
microRNA-10a in Tregs and microRNA-326 in Th17 cells43. Interestingly, microRNA-326 is driving differentia-
tion into Th17 cells by inhibiting Ets-1, a negative regulator of Th17 differentiation. In our study microRNA-326 
was down-regulated in naive T-cells after the recovery period, suggesting that differentiation into Th17 cells 
might be reduced in isotretinoin treated animals.
Interestingly, Socs3, a target gene of RA, was induced immediately after isotretinoin treatment in our in vivo 
and in vitro studies. RA in combination with RAR binds to retinoic acid responsive elements (RARE) leading 
to the expression of RA responsive genes (e.g. Socs3, Hoxa1, Hoxa4, CRBPs, and Trim16)44. Socs3 has been sug-
gested to have different effects in Teffs and Tregs. In Teffs, Socs3 inhibited STAT4 and STAT3 signaling thereby 
suppressing Th1 and Th17 responses and favoring Th2 differentiation45. In contrast, Tregs overexpression of 
Socs3 led to decreased proliferation and suppressive function46. while T-cell specific loss of Socs3 activated 
Tregs and resulted in higher production of anti-inflammatory cytokines e.g. IL-10 and TGFβ 47. Our results 
showed a significant up-regulation of Socs3 in naive T-cells directly after isotretinoin treatment suggesting a 
promotion of an anti-inflammatory profile. In Tregs from isotretinoin treated animals we observed a moderate 
upregulation of Socs3 mRNA along with the induction of mRNAs involved in IL-10 signaling. These findings 
contrast the observations by Kinjyo and colleagues46, indicating the need for further investigations into a possible 
concentration-dependent role of Socs3 on IL-10 signaling in Tregs. In naive T-cells from isotretinoin treated 
mice, the expression of Lrrk2, a susceptibility gene for IBD, was increased after the recovery phase. Lrrk2 is an 
up-stream regulator of NFAT signaling and prevents the latter to translocate into the nucleus, where NFAT has 
been shown to induce the expression of pro-inflammatory genes48,49. The overexpression of Lrrk2 in isotretinoin 
treated animals therefore further supports an anti-inflammatory effect of isotretinoin.
Despite the wide application of antibiotics, their effects on the host immune system (e.g. T-cells) have received 
limited attention. In particular differential microRNA expression in T-cells after antibiotic treatment has not been 
thoroughly characterized so far and is shown for the first time in this study.
Recent studies have shown that metronidazole, a nitroimidazole-based antibiotic frequently prescribed for 
gastrointestinal disorders is strongly associated with new-onset IBD (odds ratio 5.01)18,50. However, several 
in vivo and in vitro studies analyzing metronidazole alone or in combination with other antibiotics (ciprofloxacin, 
neomycin) showed that metronidazole exhibits direct immunosuppressive effects and ameliorates inflammatory 
conditions such as colitis51–55. Importantly, treatment of IL-10-/- mice with neomycin-metronidazole before and 
after the establishment of colitis ameliorated colitis parameter and diminished adherent bacterial levels indicating 
protective effects56. Accordingly, we also observed an anti-inflammatory effect in splenic Tregs and naive T-cells 
after treatment with metronidazole. Little is known about the long-term effects mediated by metronidazole in 
the treatment of IBD. One explanation might be long-term alterations of the gut microbiota although epigenetic 
modifications in T-cells should also be taken into account.
Tetracyclines have been shown to have immunomodulatory and anti-inflammatory effects in several inflam-
matory conditions, such as multiples sclerosis, Parkinson’s disease and rheumatoid arthritis57–60. Furthermore, 
doxycycline suppressed the proliferation of lymphocytes61 and minocycline inhibited proliferation and reduced 
production of IL-2, IFNγ and TNFα in human T-cells62. Szeto and colleagues reported that doxycycline inhib-
ited NFAT1 activation in CD4+ T-cells63. In contrast, pro-inflammatory effects have been described for dox-
ycycline in murine thymic epithelial cells. Treatment with doxycycline increased the expression of IL-6 and 
GM-CSF through activation of NFκ B and ERK indicating direct pro-inflammatory effects during homeostasis64. 
Additionally, recent epidemiological studies have shown doxycycline to be associated with CD (odds ratio 2.25)15. 
In our study we also observed an induction of pro-inflammatory pathways including NFκ B and MAPK signal-
ing in Tregs and naive T-cells directly after treatment with doxycycline. Regarding proliferation, we observed a 
downregulation of mRNAs involved in cell cycle processes that might indicate decreased proliferation of Tregs. 
The majority of studies investigated only immediate effects after doxycycline treatment, therefore and to the 
best of our knowledge, this study is describing for the first time long-term effects of this antibiotic on T-cells. To 
further elucidate potential long-term effects of isotretionin, doxycycline and metronidazole, analysis of other 
epigenetic modifications, e.g. changes in chromatin structure by ChIP-Seq or DNA methylation profiling, should 
be performed. Furthermore, it would be interesting to study epigenetic modifications and functional alterations 
in human PBMCs in response to isotretinoin, doxycycline and metronidazole treatment to see whether similar 
effects, as seen here in murine T cell subsets, can be observed.
In summary, microRNA and mRNA expression patterns in naive and regulatory T-cells suggest an 
anti-inflammatory effect of metronidazole, in contrast to doxycycline, which promoted expression patterns asso-
ciated with pro-inflammatory processes. Differential expression of microRNAs and mRNAs after the recovery 
period showed that both antibiotics might induce long-term changes in the immune phenotype in Tregs and 
naive T-cells. The observed microRNA regulation, directing to immunosuppressive modulation of T-cell func-
tion, does not support a strong impact of epigenetic modifications in the association between antibiotic treat-
ment and the development of IBD. Further investigations should address other mechanisms that might mediate 
long-term effects of drug treatment e.g. changes in gut microbiota composition, to further elucidate causal rela-
tionships between drug treatment and later development of IBD.
Methods
Mice. Female Balb/c mice were purchased from Charles River Laboratories (Germany) and housed in the 
animal facility of the University Hospital Zurich under specific pathogen-free conditions and with free access to 
food and water ad libitum.
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All animal experiments were approved by the cantonal veterinary office of Zurich under license numbers 
ZH-54-2011 and ZH-214-2016 and the methods were carried out in accordance with the institutional and state 
guidelines.
Design. T-cell samples were collected from each treatment group directly after the treatment period at week 2 
(immediate effects), and after a 4-week recovery period (week 6) without any treatment (long-term effects) 
(Fig. 1).
Animals were randomized according to weight and kept in individual cages according to treatment. The 
mice were treated daily for 2 weeks by oral gavage with the following doses: isotretinoin 30 mg/ml, or rapeseed oil 
(Brassica rapa), metronidazole 107 mg/kg, or doxycycline 43 mg/kg, or water.
In the experiments with isotretinoin for microRNA expression analysis, we pooled 4 animals to achieve 2 rep-
licates per time point and treatment, whereas for mRNA analysis we used 3–5 replicates due to quantity require-
ments of total RNA for sequencing. For the antibiotic experiments we pooled 6 animals resulting in 2 replicates 
per time point and treatment due to quantity requirements of total RNA for sequencing.
Reagents and antibodies. Isotretinoin was purchased from F. Hoffmann-La Roche Ltd (Basel, 
Switzerland). Metronidazole, doxycycline and rapeseed oil (Brassica rapa) were purchased from Sigma-Aldrich.
In order to investigate the purity of isolated CD4+ CD62L+ T-cell fraction, cells were stained with antibodies 
specific against CD4 (APC-Cy7, GK1.5), CD62L (FITC, MEL-14), CD45RB (Pacific Blue, C363-16A) and CD127 
(APC, A7R34). CD4+ CD25+ T-cell fraction was stained with antibodies against CD4 (APC-Cy7, GK1.5), 
CD25 (PE, PC61.5) and Foxp3 (APC, FJK-16s). Antibodies were obtained from either BD Pharmingen (Basel, 
Switzerland) or eBioscience (San Diego, USA). Data was collected on a FACS Canto II (BD Biosciences, Allschwil, 
Switzerland) and analysed with FlowJo software (Ashville, USA).
Mouse anti–phospho-MAPK p38 (Thr180/Tyr182), rabbit anti-p38, rabbit anti–phospho-ERK1/2 (Tyr42/Tyr44), 
rabbit anti-ERK1/2 (p44/42 MAPK), rabbit anti-phospho-MSK1 (Thr581), rabbit anti-MSK1, rabbit anti-SOCS3 
and mouse anti-GAPDH antibodies were obtained from Cell Signaling Technology (Danvers, MA).
Isolation of murine CD4+CD62L+T-cells and CD4+CD25+ T-cells. CD4+ CD62L+ and CD4+ 
CD25+ T-cells were isolated from spleens of female BALB/c mice with the CD4+ CD62L+ T-cell isolation kit II 
and CD4+ CD25+ regulatory T-cell isolation kit (Miltenyi Biotech, Bergisch Gladbach, Germany) according to 
the manufacturer’s instructions. In brief, the spleen was homogenised by passing the tissue through a nylon mesh 
(70 μ m) using a plunger. CD4+ CD62L+ and CD4+ CD25+ T-cells were purified from spleen mononuclear cells 
in two steps, i.e. depletion of non-CD4+ cells by indirect magnetic labelling with CD4+ T-cell Biotin-Antibody 
Cocktail II against CD8a, CD11b, CD45R (B220), CD49b, TCRγ /δ and Ter-119 anti-biotin microbeads, fol-
lowed by further separation of CD4+ T-cells by CD62L (L-selectin) or CD25-PE labelled immunomagnetic 
beads to positively select CD62L+ and CD25+ T-cells. Cell selection was performed using an AutoMACS sep-
arator (MiltenyiBiotec, Germany). The purity of the isolated T-cell populations was checked by FACS analysis 
(Supplementary Figure 1).
Treg suppression/Teff proliferation assay and cell culture. After magnetic sorting, responder T-cells 
(Teff; CD4+ CD25-) and regulatory T-cells (Treg; CD4+ CD25+ ) were cultured in a 96-well plate in complete 
RPMI 1640 medium (Invitrogen, Eugene, OR) which contained 2 mM L-Glutamine (Thermo Fisher, Switzerland) 
10% FCS (VWR, USA), 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich), 10 mM HEPES (Thermo 
Fisher, Switzerland), 0,1 mM nonessential amino acids and 1 mM sodium pyruvate (Sigma-Aldrich, Switzerland). 
T-cell cultures were maintained at 37 °C, 5% CO2 for 4 days. Stimulation of proliferation was achieved with 
anti-CD3/anti-CD28 coated dynabeads (Thermo Fisher, Switzerland) according to the manufacturer’s 
instructions.
Responder T-cells (Teff) from vehicle (ctrl) and isotretinoin (iso) treated animals (5 × 104 cells/well) were 
labeled with 0.5 μ M carboxyfluoresceinsuccinimidyl ester (CFSE, Sigma-Aldrich, Switzerland) at 37 °C for 10 min 
with gentle shaking and washed once with cold complete medium. Subsequently, CFSE-labeled responder T-cells 
were cultured with Tregs (decreasing numbers of Tregs: 1:2 and 1:8) or unlabeled (unlab) responders as controls. 
T-cell proliferation was assessed by the decrease of fluorescence of CFSE due to its dilution with each proliferation 
cycle. Flow cytometry was applied for fluorescence detection.
Human Jurkat cells were cultured in RPMI 1640 medium supplemented with 10% FCS and 1% L-Glutamine. 
2 × 106 cells/well were treated with isotretinoin (10 ng/ml) for 5 min, 15 min, 1 h, 3 h and 24 h and the mixture of 
100 ng/ml PMA, 1 mg/ml CD3, 1 mg/ml CD28 (positive control) at 37 °C, 5% CO2. Protein was collected for each time 
point and analyzed by western blotting.
Western Blotting. An aliquot of each lysate was mixed with an equal amount of 2 X gel loading buffer 
(50 mmol/L Tris, pH 6.8, 2% sodium dodecyl sulfate, 200 mmol/L dithiothreitol, 40% glycerol, 0.2% bromophenol 
blue) and boiled for 5 min. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electropho-
resis and transferred onto nitrocellulose membranes (Thermo Fisher, Switzerland). Membranes were blocked 
with 5% blocking solution and primary antibody was added in 5% blocking solution overnight. Membranes 
were washed 3 times with Tris-buffered saline solution containing 1% Tween 20 (1% TBST) for 15 min, 
horseradish-peroxidase-labelled secondary anti-mouse- or anti-rabbit–IgG-antibody (Santa Cruz Biotechnology) 
in 5% blocking solution (1:3000) was added for 1 h and membranes were washed 3 times for 15 min with 1% 
TBST. Finally, immunoreactive proteins were detected using an enhanced chemoluminescence detection kit (GE 
Healthcare). ImageJ was used for densitometric analysis of the blots.
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Total RNA extraction and quality/quantity analysis. After isolation of CD4+ CD62L+ and CD4+ 
CD25+ T-cells with the AutoMACS separator, extraction of total RNA including small RNA was performed with 
Qiazol (miRNeasy Kit, Qiagen, Germany) according to the manufacturer’s instructions. Before sequencing, total 
RNA was analysed on the TapeStation2200 (Agilent, Waldbronn, Germany) for defining the quality and quantity 
of all samples. Samples with a RIN-value > 6 were used for further analysis. The great majority of samples had a 
RIN-value > 9.
Sequencing procedures. mRNA sequencing. Library preparation. The TruSeq Stranded mRNA Sample 
Prep Kit (Illumina, Inc, California, USA) was used as follows: total RNA samples (100 ng) were ribosome depleted 
and reverse-transcribed into double-stranded cDNA with actinomycin added during first-strand synthesis. The 
cDNA was fragmented, end-repaired and polyadenylated before ligation of TruSeq adapters. The adapters contain 
the index for multiplexing. Fragments containing TruSeq adapters on both ends were selectively enriched with 
PCR. The quality and quantity of the enriched libraries were validated using the Tapestation (Agilent, Waldbronn, 
Germany). The product is a smear with an average fragment size of approximately 360 bp. The libraries were nor-
malized to 10 nM in Tris-Cl 10 mM, pH 8.5 with 0.1% Tween 20.
Cluster Generation and Sequencing. The TruSeq SR Cluster Kit v4-cBot-HS or TruSeq PE Cluster Kit 
v4-cBot-HS (Illumina, Inc, California, USA) was used for cluster generation using 8 pM of pooled normalized 
libraries on the cBOT. Sequencing was performed on the Illumina HiSeq 2500 single read at 1 × 125 bp using the 
TruSeq SBS Kit v4-HS (Illumina, Inc, California, USA).
microRNA sequencing. Library preparation. The NEB Next Multiplex Small RNA Sample Prep Kit (New 
England Biolabs, Inc, MA, USA) was used in the following steps. Briefly, 3’- and 5′ -RNA adapters were ligated 
to total RNA samples (1 μ g) in 2 steps. Ligated samples were reverse-transcribed into double-stranded cDNA. 
Fragments containing TruSeq adapters on both ends were selectively enriched with PCR. The 145-160 bp small 
RNA fractions were selected on 6% polyacrylamide gels. The quality and quantity of the enriched libraries were val-
idated using the Tapestation (Agilent, Waldbronn, Germany). The product is a smear with an average fragment size 
of approximately 150 bp. The libraries were normalized to 10 nM in Tris-Cl 10 mM, pH 8.5 with 0.1% Tween 20.
Cluster Generation and Sequencing. The TruSeq PE Cluster Kit v3-cBot-HS (Illumina, Inc, California, USA) 
was used for cluster generation using 10 pM of pooled normalized libraries on the cBOT. Sequencing was per-
formed on the Illumina HiSeq 2000 Single end at 1 × 50 bp using the TruSeq SBS Kit v3-HS (Illumina, Inc, 
California, USA). Data Analysis of small RNA-seq reads were quality-checked with fastqc which computes vari-
ous quality metrics for the raw reads.
Bioinformatics. Data pre-processing:. The raw fastqc reads were first cleaned by removing adapter sequences, 
trimming low quality ends, and filtering reads with low quality (phred quality < 20) using Trimmomatic65. In case 
of small RNA reads only the adapter sequences were removed.
mRNA-Sequencing. Sequence alignment of the resulting high-quality reads to the Mus musculus reference 
genome (build GRCm38) and quantification of gene level expression was carried out using RSEM (Version 
1.2.21)66. To detect differentially expressed genes, we applied the count based negative binomial model imple-
mented in the software package edgeR (R version: 3.2.0, edgeR version: 3.10.2)67, in which the normalization 
factor was calculated by trimmed mean of M values (TMM) method68. The gene-wise dispersions were esti-
mated by conditional maximum likelihood and an empirical Bayes procedure was used to shrink the dispersions 
towards a consensus value. The differential expression was assessed using an exact test adapted for over-dispersed 
data. Genes showing altered expression with adjusted P-value ≤ 0.05 were considered differentially expressed 
(Benjamini and Hochberg method). Further selection of mRNAs was done with the following threshold: |log2 
(fold change)| ≥ 0.5, P-value ≤ 0.001.
microRNA-Sequencing. Sequence alignment, quantification and quality control were performed using ncPRO 
(version 1.5.1)69. The microRNA annotation is based on miRBase version 20. Differentially expressed microRNAs 
were identified applying edgeR. Further selection of microRNAs was done with the following thresholds: |log2 
(fold change)| ≥ 1, P-value ≤ 0.001.
microRNA targets and mRNA correlation. Predicted microRNA targets were analyzed with TargetScan (Version 
6.2) and TargetScan custom (Version 5.2). Pathway analyses were performed with MetaCore by Thomson Reuters 
(Version 6.24). For identification of enriched pathways the Metacore variation of the Fisher’s exact test and cor-
rection for multiple sample testing by FDR was applied.
Statistical Analysis. Statistical comparisons were performed by two tailed Student’s test. P-values ≤ 0.05 
were considered statistically significant.
References
1. Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic 
review. Gastroenterology 142, 46–54 e42; quiz e30, doi: 10.1053/j.gastro.2011.10.001 (2012).
2. Khor, B., Gardet, A. & Xavier, R. J. Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307–317, doi: 10.1038/
nature10209 (2011).
3. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124, 
doi: 10.1038/nature11582 (2012).
www.nature.com/scientificreports/
1 4Scientific RepoRts | 6:37082 | DOI: 10.1038/srep37082
4. Huang, C. et al. Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans. 
Gastroenterology 149, 1575–1586, doi: 10.1053/j.gastro.2015.07.065 (2015).
5. Liu, J. Z. et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk 
across populations. Nat Genet 47, 979–986, doi: 10.1038/ng.3359 (2015).
6. Iborra, M., Bernuzzi, F., Invernizzi, P. & Danese, S. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators 
in immune response. Autoimmun Rev 11, 305–314, doi: 10.1016/j.autrev.2010.07.002 (2012).
7. Kalla, R. et al. MicroRNAs: new players in IBD. Gut 64, 504–517, doi: 10.1136/gutjnl-2014-307891 (2015).
8. Pekow, J. R. & Kwon, J. H. MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis 18, 187–193, doi: 10.1002/ibd.21691 
(2012).
9. Ma, X. et al. Expression, regulation and function of microRNAs in multiple sclerosis. Int J Med Sci 11, 810–818, doi: 10.7150/
ijms.8647 (2014).
10. Huang, R. Y. et al. An Exploration of the Role of MicroRNAs in Psoriasis: A Systematic Review of the Literature. Medicine 
(Baltimore) 94, e2030, doi: 10.1097/MD.0000000000002030 (2015).
11. Amarilyo, G. & La Cava, A. miRNA in systemic lupus erythematosus. Clin Immunol 144, 26–31, doi: 10.1016/j.clim.2012.04.005 
(2012).
12. Sedivy, J. M., Banumathy, G. & Adams, P. D. Aging by epigenetics–a consequence of chromatin damage? Exp Cell Res 314, 
1909–1917, doi: 10.1016/j.yexcr.2008.02.023 (2008).
13. Li, Z. & Rana, T. M. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 13, 622–638, 
doi: 10.1038/nrd4359 (2014).
14. Hviid, A., Svanstrom, H. & Frisch, M. Antibiotic use and inflammatory bowel diseases in childhood. Gut 60, 49–54, doi: 10.1136/
gut.2010.219683 (2011).
15. Margolis, D. J., Fanelli, M., Hoffstad, O. & Lewis, J. D. Potential association between the oral tetracycline class of antimicrobials used 
to treat acne and inflammatory bowel disease. The American journal of gastroenterology 105, 2610–2616, doi: 10.1038/ajg.2010.303 
(2010).
16. Shaw, S. Y., Blanchard, J. F. & Bernstein, C. N. Association between the use of antibiotics in the first year of life and pediatric 
inflammatory bowel disease. The American journal of gastroenterology 105, 2687–2692, doi: 10.1038/ajg.2010.398 (2010).
17. Shaw, S. Y., Blanchard, J. F. & Bernstein, C. N. Association between the use of antibiotics and new diagnoses of Crohn’s disease and 
ulcerative colitis. The American journal of gastroenterology 106, 2133–2142, doi: 10.1038/ajg.2011.304 (2011).
18. Ungaro, R. et al. Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a meta-analysis. 
The American journal of gastroenterology 109, 1728–1738, doi: 10.1038/ajg.2014.246 (2014).
19. Crockett, S. D., Porter, C. Q., Martin, C. F., Sandler, R. S. & Kappelman, M. D. Isotretinoin use and the risk of inflammatory bowel 
disease: a case-control study. The American journal of gastroenterology 105, 1986–1993, doi: 10.1038/ajg.2010.124 (2010).
20. Reddy, D., Siegel, C. A., Sands, B. E. & Kane, S. Possible association between isotretinoin and inflammatory bowel disease. The 
American journal of gastroenterology 101, 1569–1573, doi: 10.1111/j.1572-0241.2006.00632.x (2006).
21. Shale, M., Kaplan, G. G., Panaccione, R. & Ghosh, S. Isotretinoin and intestinal inflammation: what gastroenterologists need to 
know. Gut 58, 737–741, doi: 10.1136/gut.2008.170530 (2009).
22. Bernstein, C. N., Nugent, Z., Longobardi, T. & Blanchard, J. F. Isotretinoin is not associated with inflammatory bowel disease: a 
population-based case-control study. The American journal of gastroenterology 104, 2774–2778, doi: 10.1038/ajg.2009.417 (2009).
23. Popescu, C. M. & Popescu, R. Isotretinoin therapy and inflammatory bowel disease. Arch Dermatol 147, 724–729, doi: 10.1001/
archdermatol.2011.116 (2011).
24. Thakrar, B. T. & Robinson, N. J. Isotretinoin use and the risk of inflammatory bowel disease. The American journal of gastroenterology 
106, 1000–1002; author reply 1002-1003, doi: 10.1038/ajg.2011.28 (2011).
25. Williams, H. C., Dellavalle, R. P. & Garner, S. Acne vulgaris. Lancet 379, 361–372, doi: 10.1016/S0140-6736(11)60321-8 (2012).
26. Bachstetter, A. D. & Van Eldik, L. J. The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in 
Degenerative Diseases of the CNS. Aging Dis 1, 199–211 (2010).
27. Piskunov, A. & Rochette-Egly, C. A retinoic acid receptor RARalpha pool present in membrane lipid rafts forms complexes with G 
protein alphaQ to activate p38MAPK. Oncogene 31, 3333–3345, doi: 10.1038/onc.2011.499 (2012).
28. Pasquinelli, A. E. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 13, 
271–282, doi: 10.1038/nrg3162 (2012).
29. Philllips, T. Regulation of Transcription and Gene Expression in Eukaryotes. Nature Education 1, 199 (2008).
30. Phillips, T. Small non-coding RNA and gene expression. Nature Education 1, 115 (2008).
31. Baek, D. et al. The impact of microRNAs on protein output. Nature 455, 64–71, doi: 10.1038/nature07242 (2008).
32. Mehta, A. & Baltimore, D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol 16, 279–294, doi: 10.1038/
nri.2016.40 (2016).
33. Wang, Z. et al. Transcriptional and epigenetic regulation of human microRNAs. Cancer Lett 331, 1–10, doi: 10.1016/j.
canlet.2012.12.006 (2013).
34. Chen, W. X., Ren, L. H. & Shi, R. H. Implication of miRNAs for inflammatory bowel disease treatment: Systematic review. World J 
Gastrointest Pathophysiol 5, 63–70, doi: 10.4291/wjgp.v5.i2.63 (2014).
35. Fisher, K. & Lin, J. MicroRNA in inflammatory bowel disease: Translational research and clinical implication. World J Gastroenterol 
21, 12274–12282, doi: 10.3748/wjg.v21.i43.12274 (2015).
36. Runtsch, M. C., Round, J. L. & O’Connell, R. M. MicroRNAs and the regulation of intestinal homeostasis. Front Genet 5, 347, 
doi: 10.3389/fgene.2014.00347 (2014).
37. Schaefer, J. S. et al. MicroRNA signatures differentiate Crohn’s disease from ulcerative colitis. BMC Immunol 16, 5, doi: 10.1186/
s12865-015-0069-0 (2015).
38. Wu, F. et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 
alpha. Gastroenterology 135, 1624–1635 e1624, doi: 10.1053/j.gastro.2008.07.068 (2008).
39. Hall, J. A., Grainger, J. R., Spencer, S. P. & Belkaid, Y. The role of retinoic acid in tolerance and immunity. Immunity 35, 13–22, doi: 
10.1016/j.immuni.2011.07.002 (2011).
40. Liu, Z. M., Wang, K. P., Ma, J. & Guo Zheng, S. The role of all-trans retinoic acid in the biology of Foxp3+ regulatory T cells. Cell Mol 
Immunol 12, 553–557, doi: 10.1038/cmi.2014.133 (2015).
41. Mucida, D. et al. Retinoic acid can directly promote TGF-beta-mediated Foxp3(+ ) Treg cell conversion of naive T cells. Immunity 
30, 471–472; author reply 472-473, doi: 10.1016/j.immuni.2009.03.008 (2009).
42. Zhou, X. et al. Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory 
milieu. J Immunol 185, 2675–2679, doi: 10.4049/jimmunol.1000598 (2010).
43. Dooley, J., Linterman, M. A. & Liston, A. MicroRNA regulation of T-cell development. Immunol Rev 253, 53–64, doi: 10.1111/
imr.12049 (2013).
44. Piskunov, A., Al Tanoury, Z. & Rochette-Egly, C. Nuclear and extra-nuclear effects of retinoid acid receptors: how they are 
interconnected. Subcell Biochem 70, 103–127, doi: 10.1007/978-94-017-9050-5_6 (2014).
45. Palmer, D. C. & Restifo, N. P. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends 
Immunol 30, 592–602, doi: 10.1016/j.it.2009.09.009 (2009).
www.nature.com/scientificreports/
1 5Scientific RepoRts | 6:37082 | DOI: 10.1038/srep37082
46. Pillemer, B. B., Xu, H., Oriss, T. B., Qi, Z. & Ray, A. Deficient SOCS3 expression in CD4+ CD25+ FoxP3+ regulatory T cells and 
SOCS3-mediated suppression of Treg function. Eur J Immunol 37, 2082–2089, doi: 10.1002/eji.200737193 (2007).
47. Kinjyo, I. et al. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and 
transforming growth factor-beta 1. J Exp Med 203, 1021–1031, doi: 10.1084/jem.20052333 (2006).
48. Liu, Z. et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel 
disease. Nat Immunol 12, 1063–1070, doi: 10.1038/ni.2113 (2011).
49. Weigmann, B. et al. The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. The Journal 
of experimental medicine 205, 2099–2110, doi: 10.1084/jem.20072484 (2008).
50. Pelissier, M. A. et al. Metronidazole effects on microbiota and mucus layer thickness in the rat gut. FEMS Microbiol Ecol 73, 601–610, 
doi: 10.1111/j.1574-6941.2010.00916.x (2010).
51. Bamias, G. et al. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a 
murine model of Crohn’s disease. J Immunol 169, 5308–5314 (2002).
52. Colpaert, S. et al. Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel 
inflammation rat model. Aliment Pharmacol Ther 15, 1827–1836 (2001).
53. Fararjeh, M., Mohammad, M. K., Bustanji, Y., Alkhatib, H. & Abdalla, S. Evaluation of immunosuppression induced by 
metronidazole in Balb/c mice and human peripheral blood lymphocytes. International immunopharmacology 8, 341–350, 
doi: 10.1016/j.intimp.2007.10.018 (2008).
54. Khan, K. J. et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. The American journal of 
gastroenterology 106, 661–673, doi: 10.1038/ajg.2011.72 (2011).
55. Wang, S. L., Wang, Z. R. & Yang, C. Q. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory 
bowel disease. Exp Ther Med 4, 1051–1056, doi: 10.3892/etm.2012.718 (2012).
56. Madsen, K. L. et al. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 118, 1094–1105 
(2000).
57. Griffin, M. O., Fricovsky, E., Ceballos, G. & Villarreal, F. Tetracyclines: a pleitropic family of compounds with promising therapeutic 
properties. Review of the literature. Am J Physiol Cell Physiol 299, C539–C548, doi: 10.1152/ajpcell.00047.2010 (2010).
58. O’Dell, J. R. et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, 
placebo-controlled trial. Arthritis Rheum 40, 842–848, doi: 10.1002/1529-0131(199705)40:5&lt;842::AID-ART9&gt;3.0.CO;2-1 
(1997).
59. Popovic, N. et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 51, 215–223 (2002).
60. Yi, C. et al. Doxycycline attenuates peripheral inflammation in rat experimental autoimmune neuritis. Neurochem Res 36, 
1984–1990, doi: 10.1007/s11064-011-0522-2 (2011).
61. Banck, G. & Forsgren, A. Antibiotics and suppression of lymphocyte function in vitro. Antimicrobial agents and chemotherapy 16, 
554–560 (1979).
62. Kloppenburg, M. et al. The influence of tetracyclines on T cell activation. Clinical and experimental immunology 102, 635–641 
(1995).
63. Szeto, G. L., Pomerantz, J. L., Graham, D. R. & Clements, J. E. Minocycline suppresses activation of nuclear factor of activated T cells 
1 (NFAT1) in human CD4+ T cells. J Biol Chem 286, 11275–11282, doi: 10.1074/jbc.M110.210518 (2011).
64. Huang, Y. et al. Doxycycline up-regulates the expression of IL-6 and GM-CSF via MAPK/ERK and NF-kappaB pathways in mouse 
thymic epithelial cells. International immunopharmacology 11, 1143–1149, doi: 10.1016/j.intimp.2011.03.011 (2011).
65. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120, 
doi: 10.1093/bioinformatics/btu170 (2014).
66. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC 
Bioinformatics 12, 323, doi: 10.1186/1471-2105-12-323 (2011).
67. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene 
expression data. Bioinformatics 26, 139–140, doi: 10.1093/bioinformatics/btp616 (2010).
68. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome 
biology 11, R25, doi: 10.1186/gb-2010-11-3-r25 (2010).
69. Chen, C. J. et al. ncPRO-seq: a tool for annotation and profiling of ncRNAs in sRNA-seq data. Bioinformatics 28, 3147–3149, 
doi: 10.1093/bioinformatics/bts587 (2012).
Acknowledgements
The authors thank Dr. Lutz Müller from Roche for helpful discussions and assistance during the course of these 
studies. We are grateful for the excellent technical support from Silvia Lang and Dr. Marianne Spalinger.
Author Contributions
Animal care, recording of weight curves (E.B., S.B., K.A.). Drug application (E.B., K.A.). Euthanasia of mice and 
sampling (E.B., S.B., K.A.). T-cell isolation (E.B.). Sample preparation for sequencing (E.B., S.A.). Bioinformatic 
analysis (E.B., L.O.). Proliferation Assay (E.B.). Western Blot Analysis (E.B.). Study design (E.B., C.S., P.R., G.R., 
I.F.W.). Preparation of the manuscript (E.B., G.R., I.F.W.). Figure design and arrangement (E.B.). All authors 
reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: F. Hoffmann-La Roche, Ltd. (Basel, Switzerland) supported this study by 
an unrestricted research grant. Responsibility for opinions, conclusions, and interpretation of data lies with 
the authors. No author receives stipends or acts in any other consultative capacity for Roche. Roche had no 
influence on the design of the studies presented but approved the study protocol developed by the investigators. 
All analyses were performed solely by the investigators; Roche had no influence on the analyses performed or 
data interpretation. Decisions as to the data presented were made solely by the investigators with no input from 
Roche. Manuscript development, review and editing were performed without any input from, or sharing with 
Roche at any point. Roche provided only financial resources with no access to content.
How to cite this article: Becker, E. et al. Doxycycline, metronidazole and isotretinoin: Do they modify 
microRNA/mRNA expression profiles and function in murine T-cells? Sci. Rep. 6, 37082; doi: 10.1038/
srep37082 (2016).
www.nature.com/scientificreports/
1 6Scientific RepoRts | 6:37082 | DOI: 10.1038/srep37082
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
